Protective humoral immune response induced by an inactivated porcine reproductive and respiratory syndrome virus expressing the hypo-glycosylated glycoprotein 5

Vaccine

Volumn 32, Issue 29, 2014, Pages 3617-3622

  Lee, Jung Ah ^a   Kwon, Byungjoon ^b   Osorio, Fernando A ^b   Pattnaik, Asit K ^b   Lee, Nak Hyung ^a   Lee, Sang Won ^a   Park, Seung Yong ^a   Song, Chang Seon ^a   Choi, In Soo ^a   Lee, Joong Bok ^a  

^a Konkuk University   (South Korea)

^b UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

GP5; Humoral immune response; Hypo glycosylation; Inactivated virus vaccine; PRRSV

Indexed keywords

AZIRIDINE; HYPOGLYCOSYLATED GLYCOPROTEIN 5; INACTIVATED PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE; INACTIVATED VIRUS VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; GLYCOPROTEIN 5, PRRSV; INACTIVATED VACCINE; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN; VIRUS VACCINE;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DEGLYCOSYLATION; DRUG EFFICACY; HISTOPATHOLOGY; HUMORAL IMMUNITY; IMMUNOGENICITY; LUNG ALVEOLUS WALL; LUNG INFILTRATE; LUNG PARENCHYMA; LYMPHOCYTIC INFILTRATION; NONHUMAN; PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; TREATMENT OUTCOME; VACCINATION; VIRAL CLEARANCE; VIRUS MUTANT; ANIMAL; ARTERIVIRUS; BLOOD; GENETICS; GLYCOSYLATION; IMMUNOLOGY; LUNG; PATHOLOGY; SERODIAGNOSIS; SWINE; VIREMIA;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; GLYCOSYLATION; IMMUNITY, HUMORAL; LUNG; NEUTRALIZATION TESTS; PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME; PORCINE RESPIRATORY AND REPRODUCTIVE SYNDROME VIRUS; SWINE; VACCINES, INACTIVATED; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES; VIREMIA;

EID: 84901604609     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.04.083     Document Type: Article

References (58)

1. Wee G.J., et al. Efficacy of porcine reproductive and respiratory syndrome virus vaccine and porcine interleukin-12. Vet Ther 2001, 2(2):112-119.
2. Christianson W.T., et al. Experimental reproduction of swine infertility and respiratory syndrome in pregnant sows. Am J Vet Res 1992, 53(4):485-488.
3. Nodelijk G., et al. A quantitative assessment of the effectiveness of PRRSV vaccination in pigs under experimental conditions. Vaccine 2001, 19(27):3636-3644.
4. Kwang J., et al. Antibody and cellular immune responses of swine following immunisation with plasmid DNA encoding the PRRS virus ORF's 4, 5, 6 and 7. Res Vet Sci 1999, 67(2):199-201.
5. Neumann E.J., et al. Assessment of the economic impact of porcine reproductive and respiratory syndrome on swine production in the United States. J Am Vet Med Assoc 2005, 227(3):385-392.
6. Corzo C.A., et al. Control and elimination of porcine reproductive and respiratory syndrome virus. Virus Res 2010, 154(1-2):185-192.
7. Blaha T. The "colorful" epidemiology of PRRS. Vet Res 2000, 31(1):77-83.
8. Meng X.J. Heterogeneity of porcine reproductive and respiratory syndrome virus: implications for current vaccine efficacy and future vaccine development. Vet Microbiol 2000, 74(4):309-329.
9. Murtaugh M.P., Xiao Z., Zuckermann F. Immunological responses of swine to porcine reproductive and respiratory syndrome virus infection. Viral Immunol 2002, 15(4):533-547.
10. Batista L., et al. Detection of porcine reproductive and respiratory syndrome virus in pigs with low positive or negative ELISA s/p ratios. Vet Rec 2004, 154(1):25-26.
11. Nilubol D., et al. The effect of a killed porcine reproductive and respiratory syndrome virus (PRRSV) vaccine treatment on virus shedding in previously PRRSV infected pigs. Vet Microbiol 2004, 102(1-2):11-18.
12. Scortti M., et al. Failure of an inactivated vaccine against porcine reproductive and respiratory syndrome to protect gilts against a heterologous challenge with PRRSV. Vet Rec 2007, 161(24):809-813.
13. Zuckermann F.A., et al. Assessment of the efficacy of commercial porcine reproductive and respiratory syndrome virus (PRRSV) vaccines based on measurement of serologic response, frequency of gamma-IFN-producing cells and virological parameters of protection upon challenge. Vet Microbiol 2007, 123(1-3):69-85.
14. Misinzo G., et al. Efficacy of an inactivated PRRSV vaccine: induction of virus-neutralizing antibodies and partial virological protection upon challenge. Adv Exp Med Biol 2006, 581:449-454.
15. Huang Y.W., Meng X.J. Novel strategies and approaches to develop the next generation of vaccines against porcine reproductive and respiratory syndrome virus (PRRSV). Virus Res 2010, 154(1-2):141-149.
16. Kimman T.G., et al. Challenges for porcine reproductive and respiratory syndrome virus (PRRSV) vaccinology. Vaccine 2009, 27(28):3704-3718.
17. van Nieuwstadt A.P., et al. Proteins encoded by open reading frames 3 and 4 of the genome of Lelystad virus (Arteriviridae) are structural proteins of the virion. J Virol 1996, 70(7):4767-4772.
18. Yang L., et al. Categorization of North American porcine reproductive and respiratory syndrome viruses: epitopic profiles of the N, M, GP5 and GP3 proteins and susceptibility to neutralization. Arch Virol 2000, 145(8):1599-1619.
19. Cancel-Tirado S.M., Evans R.B., Yoon K.J. Monoclonal antibody analysis of porcine reproductive and respiratory syndrome virus epitopes associated with antibody-dependent enhancement and neutralization of virus infection. Vet Immunol Immunopathol 2004, 102(3):249-262.
20. Gonin P., et al. Seroneutralization of porcine reproductive and respiratory syndrome virus correlates with antibody response to the GP5 major envelope glycoprotein. J Vet Diagn Invest 1999, 11(1):20-26.
21. Weiland E., et al. Monoclonal antibodies to the GP5 of porcine reproductive and respiratory syndrome virus are more effective in virus neutralization than monoclonal antibodies to the GP4. Vet Microbiol 1999, 66(3):171-186.
22. Ostrowski M., et al. Identification of neutralizing and nonneutralizing epitopes in the porcine reproductive and respiratory syndrome virus GP5 ectodomain. J Virol 2002, 76(9):4241-4250.
23. Plagemann P.G., Rowland R.R., Faaberg K.S. The primary neutralization epitope of porcine respiratory and reproductive syndrome virus strain VR-2332 is located in the middle of the GP5 ectodomain. Arch Virol 2002, 147(12):2327-2347.
24. Delputte P.L., et al. Effect of virus-specific antibodies on attachment, internalization and infection of porcine reproductive and respiratory syndrome virus in primary macrophages. Vet Immunol Immunopathol 2004, 102(3):179-188.
25. Delputte P.L., et al. Porcine arterivirus attachment to the macrophage-specific receptor sialoadhesin is dependent on the sialic acid-binding activity of the N-terminal immunoglobulin domain of sialoadhesin. J Virol 2007, 81(17):9546-9550.
26. Lopez O.J., Osorio F.A. Role of neutralizing antibodies in PRRSV protective immunity. Vet Immunol Immunopathol 2004, 102(3):155-163.
27. Yoon K.J., et al. Characterization of the humoral immune response to porcine reproductive and respiratory syndrome (PRRS) virus infection. J Vet Diagn Invest 1995, 7(3):305-312.
28. Albina E., et al. Immune responses in pigs infected with porcine reproductive and respiratory syndrome virus (PRRSV). Vet Immunol Immunopathol 1998, 61(1):49-66.
29. Labarque G.G., et al. Effect of cellular changes and onset of humoral immunity on the replication of porcine reproductive and respiratory syndrome virus in the lungs of pigs. J Gen Virol 2000, 81(Pt 5):1327-1334.
30. Music N., Gagnon C.A. The role of porcine reproductive and respiratory syndrome (PRRS) virus structural and non-structural proteins in virus pathogenesis. Anim Health Res Rev 2010, 11(2):135-163.
31. Ansari I.H., et al. Influence of N-linked glycosylation of porcine reproductive and respiratory syndrome virus GP5 on virus infectivity, antigenicity, and ability to induce neutralizing antibodies. J Virol 2006, 80(8):3994-4004.
32. Faaberg K.S., et al. Neutralizing antibody responses of pigs infected with natural GP5 N-glycan mutants of porcine reproductive and respiratory syndrome virus. Viral Immunol 2006, 19(2):294-304.
33. Jiang W., et al. Influence of porcine reproductive and respiratory syndrome virus GP5 glycoprotein N-linked glycans on immune responses in mice. Virus Genes 2007, 35(3):663-671.
34. Vu H.L., et al. Immune evasion of porcine reproductive and respiratory syndrome virus through glycan shielding involves both glycoprotein 5 as well as glycoprotein 3. J Virol 2011, 85(11):5555-5564.
35. Skehel J.J., et al. A carbohydrate side chain on hemagglutinins of Hong Kong influenza viruses inhibits recognition by a monoclonal antibody. Proc Nat Acad Sci USA 1984, 81(6):1779-1783.
36. Chen Z., Li K., Plagemann P.G. Neuropathogenicity and sensitivity to antibody neutralization of lactate dehydrogenase-elevating virus are determined by polylactosaminoglycan chains on the primary envelope glycoprotein. Virology 2000, 266(1):88-98.
37. Lee C.M., et al. Prevalence and clinical implications of hepatitis B virus genotypes in southern Taiwan. Scand J Gastroenterol 2003, 38(1):95-101.
38. Wei X., et al. Antibody neutralization and escape by HIV-1. Nature 2003, 422(6929):307-312.
39. Li B., et al. Immunogenicity of the highly pathogenic porcine reproductive and respiratory syndrome virus GP5 protein encoded by a synthetic ORF5 gene. Vaccine 2009, 27(13):1957-1963.
40. Wei Z., et al. N-linked glycosylation of GP5 of porcine reproductive and respiratory syndrome virus is critically important for virus replication in vivo. J Virol 2012, 86(18):9941-9951.
41. Truong H.M., et al. A highly pathogenic porcine reproductive and respiratory syndrome virus generated from an infectious cDNA clone retains the in vivo virulence and transmissibility properties of the parental virus. Virology 2004, 325(2):308-319.
42. Kim H.S., et al. Enhanced replication of porcine reproductive and respiratory syndrome (PRRS) virus in a homogeneous subpopulation of MA-104 cell line. Arch Virol 1993, 133(3-4):477-483.
43. Bahnemann H.G. Inactivation of viral antigens for vaccine preparation with particular reference to the application of binary ethylenimine. Vaccine 1990, 8(4):299-303.
44. Jang S.I., et al. Montanide IMS 1313 N VG PR nanoparticle adjuvant enhances antigen-specific immune responses to profilin following mucosal vaccination against Eimeria acervulina. Vet Parasitol 2011, 182(2-4):163-170.
45. Cloete M., et al. Evaluation of different adjuvants for foot-and-mouth disease vaccine containing all the SAT serotypes. Onderstepoort J Vet Res 2008, 75(1):17-31.
46. Bentley K., Armesto M., Britton P. Infectious bronchitis virus as a vector for the expression of heterologous genes. PLoS One 2013, 8(6):e67875.
47. Ni Y.Y., et al. Attenuation of porcine reproductive and respiratory syndrome virus by molecular breeding of virus envelope genes from genetically divergent strains. J Virol 2013, 87(1):304-313.
48. Bastos R.G., et al. Immune response of pigs inoculated with Mycobacterium bovis BCG expressing a truncated form of GP5 and M protein of porcine reproductive and respiratory syndrome virus. Vaccine 2004, 22(3-4):467-474.
49. Kheyar A., et al. Alternative codon usage of PRRS virus ORF5 gene increases eucaryotic expression of GP(5) glycoprotein and improves immune response in challenged pigs. Vaccine 2005, 23(31):4016-4022.
50. Osorio F.A., et al. Passive transfer of virus-specific antibodies confers protection against reproductive failure induced by a virulent strain of porcine reproductive and respiratory syndrome virus and establishes sterilizing immunity. Virology 2002, 302(1):9-20.
51. Nielsen T.L., et al. Examination of virus shedding in semen from vaccinated and from previously infected boars after experimental challenge with porcine reproductive and respiratory syndrome virus. Vet Microbiol 1997, 54(2):101-112.
52. Vanhee M., et al. Development of an experimental inactivated PRRSV vaccine that induces virus-neutralizing antibodies. Vet Res 2009, 40(6):63.
53. Dwivedi V., et al. Biodegradable nanoparticle-entrapped vaccine induces cross-protective immune response against a virulent heterologous respiratory viral infection in pigs. PLoS One 2012, 7(12):e51794.
54. Dwivedi V., et al. PLGA nanoparticle entrapped killed porcine reproductive and respiratory syndrome virus vaccine helps in viral clearance in pigs. Vet Microbiol 2013, 166(1-2):47-58.
55. Delrue I., Delputte P.L., Nauwynck H.J. Assessing the functionality of viral entry-associated domains of porcine reproductive and respiratory syndrome virus during inactivation procedures, a potential tool to optimize inactivated vaccines. Vet Res 2009, 40(6):62.
56. Habib M., et al. Inactivation of infectious bursal disease virus by binary ethylenimine and formalin. J Zhejiang Univ Sci B 2006, 7(4):320-323.
57. Kim H., et al. The assessment of efficacy of porcine reproductive respiratory syndrome virus inactivated vaccine based on the viral quantity and inactivation methods. Virol J 2011, 8:323.
58. Geldhof M.F., et al. Comparison of the efficacy of autogenous inactivated Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) vaccines with that of commercial vaccines against homologous and heterologous challenges. BMC Vet Res 2012, 8:182.